News Johnson & Johnson BOERSE MUENCHEN

Equities

JNJ

US4781601046

Real-time BOERSE MUENCHEN Other stock markets 15:30:56 29/05/2024 BST			5-day change	1st Jan Change
133.7 ^EUR	+0.53%		-4.54%	-6.06%

03:01pm	Johnson & Johnson's Phase 3 Trial of Seltorexant to Treat Major Depressive Disorder Meets Primary, Secondary Endpoints	MT
02:08pm	J&J's treatment for depression succeeds in late stage study	RE

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Johnson & Johnson's Phase 3 Trial of Seltorexant to Treat Major Depressive Disorder Meets Primary, Secondary Endpoints	02:01pm	MT
J&J's treatment for depression succeeds in late stage study	01:08pm	RE
NanoViricides (NNVC) Strengthens Drug Development Efforts with Calvert Labs Partnership and Announces Promising RSV Study Results	10:08am	AQ
Sector Update: Health Care Stocks Fall Late Afternoon	05-28	MT
Sector Update: Health Care Stocks Retreat Tuesday Afternoon	05-28	MT
Sector Update: Health Care	05-28	MT
Bio-Thera, Stada Enter Deal for Biosimilar Candidate to Johnson & Johnson's Simponi in EU, UK	05-28	MT
Johnson & Johnson Agrees to Buy Numab Unit, Investigational Skin Disease Treatment For $1.25 Billion	05-28	MT
Top Midday Stories: Wall Street Returns to T+1 Settlements; T-Mobile Buys US Cellular's Wireless Ops; Energy Transfer Buys WTG Midstream; GameStop Extends Rally	05-28	MT
Johnson & Johnson to Acquire Experimental Eczema Drug for $1.25 Billion	05-28	MT
Johnson & Johnson to Acquire Experimental Eczema Drug for $1.25 Billion	05-28	MT
Johnson & Johnson Acquires Experimental Eczema Drug for $1.25 Billion	05-28	MT
J&J: acquisition of Swiss eczema biotech company	05-28	CF
J&J to Acquire Skin Disease Treatment Rights from Numab in $1.25 Billion Deal	05-28	DJ
J&J acquires rights to skin disorder drug for $1.25 bln	05-28	RE
Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for the Treatment of Atopic Dermatitis	05-28	AQ
Johnson & Johnson to Obtain Rights to a Clinical-Stage Bispecific Antibody to Address Distinct Patient Needs in Atopic Dermatitis	05-28	BU
Johnson & Johnson: Meet a nurse who leads clinical trials to find innovative cancer therapies	05-24	AQ
J&J: to present advances at ASCO and EHA	05-24	CF
Johnson & Johnson : advances leadership in oncology innovation with more than 75 clinical study and real-world presentations at ASCO and EHA	05-24	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 05:30 pm